期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型血管紧张素转换酶抑制剂喹那普利的研究进展 被引量：1

The Progress in Research of Quinapril, a New Angiotensin-Converting Enzyme Inhibitor
下载PDF
导出
摘要 重点介绍喹那普利的作用特点以及在临床中的应用。喹那普利能有效地治疗高血压和充血性心力衰竭,近年来在心肌缺血、左室肥厚、糖尿病肾病、保护肾功能、改善内皮功能障碍、调节血脂以及溶解血栓等疾病的防治中也发挥着越来越重要的作用。 In this article, we mainly introduced the action characteristic of quinapril and its clinicalapplication. Quinapril is not only effective in treating hypertension and congestive heart failure, but alsoplaying a more important role in preventing and treating myocardial ischemia, left ventricle thickening anddiabetic nephropathy, protecting renal function,improving endothelium dysfunction, modulating blood lipidsand dissolving thrombus.
作者 丁海英 赵芳 陈伟 许凯 高春环
机构地区 哈药集团制药总厂
出处 《中国处方药》 2005年第1期78-80,共3页 Journal of China Prescription Drug
关键词 喹那普利 血管紧张素转换酶抑制剂 治疗 内皮功能障碍 溶解血栓 研究进展 心肌缺血 作用 改善 保护 ACE inhibitors quinapril action characteristic clinical application
分类号 R972 [医药卫生—药品]
  • 相关文献

参考文献7

  • 1Franz IW;Tonnesmann U;Muller JF.Time course of complete normalization of left ventricular hypertrophy during long-time antihypertensive therapy with angiotensin converting enzyme inhibitors[J],1998(06).
  • 2洪中立,曲静伟,李明白,董采予.高血压合并左心室肥大的药物治疗[J].国外医药（合成药．生化药．制剂分册）,1991,12(1):15-17. 被引量：1
  • 3刘明蓉,吴苏澄,陈宜彬.新的转换酶抑制剂——喹那普利[J].国外医药（合成药．生化药．制剂分册）,1991,12(6):343-346. 被引量：1
  • 4郑幼兰,林建峰,朱惠,李勇.抗高血压药物血管紧张素Ⅱ的1型受体阻断剂研究进展[J].海峡药学,2003,15(3):1-5. 被引量：6
  • 5盐酸喹那普利治疗原发性高血压的临床应用观察协作组.盐酸喹那普利治疗原发性高血压的临床应用观察[J]哈尔滨医科大学学报,2000(12).
  • 6Alison N;Wadworth;Rex N.Quinapril Review of its Pharmacological Properties,and Therapeutic Efficacy in Cardiovascular Disorders[J],1991(03).
  • 7Bruno Fabris;Bingzhong Chen;Vicki Pupic.Inhibition of Angiotensin-Converting Enzyme(ACE) in Plasma and Tissue,1990(02).

二级参考文献41

  • 1袁洪 叶显华 见袁洪 杨促主编.血管紧张素Ⅱ受体拮抗剂[A].见袁洪、杨促主编.老年高血压,第一版[C].北京,人民卫生出版社,2002.121～124.
  • 2陈修 陈修 陈维洲 曾贵云主编.血管紧张素Ⅱ的1型受体阻断剂[A].陈修,陈维洲,曾贵云主编.心血管药理学,第三版[C].北京,人民卫生出版社,2001.361～368.
  • 3Lo MW, Goldberg MR, Mccrea JB, et al. Pharmacokinetic of losartan, an angiotensin Ⅱ receptor antagonist and it active metabolite EXP3174 in human. Clin Pharmacol Ther 1995,58 (6) , 641-649.
  • 4Yu G, Liang X, Xie X, et al. Apoptosis, myocardial fibrosis and angiotensin Ⅱ in the left ventricle of hypertensive rats treated with fosinopril or losartan. Chin Med J (Engl) 2002, 115 (9) : 1287-1291.
  • 5Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium an angiotension Ⅱ receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensionconverting enzyme inhibiters for the treatment of systemic hypertension,Am J Cardiol 1995,75(12): 793-795.
  • 6Weir MR, Elkins M, Liss C, et al. Efficacy, tolerability and guality of life of losartan, alone or with hydrochlorothiazide, versus nifedepine GITS in patient with essential hypertension. Clln Ther 1996,18 (3) , 411-428.
  • 7Gradman AH, Brady WE, Gazdich LP, et al. A multicenter,randomized, double-blind placebo controlled, 8 week trial of the efficacy and tohrability of one-daily lOOmg losartan/hydrochlorothiazide 25mg and losartan 50mg/hydrochlorothiazide 12.5mg in the treatment of moderate-severe essential hypertension. Clin Ther 2002,24(7) : 1049-1061.
  • 8Goa KL, Wagataff A.I. Losartan potassium, a review of its pharmacology clinical efficacy and tolerability in the management of hypertension. Drugs 1996,51(6) : 820-845.
  • 9Waldmeier F, Flesch G, Muller P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelhd vaisartan in healthy male volunteers after a single oral dose. Xenobiotiea 1997,27 (1) : 59-71.
  • 10Oparis s, Dykes S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996,18(5) : 797-810.

共引文献5

同被引文献10

  • 1Prieto JA, Jimenez RM, Alonso RM. Square wave vohammetric determination of the angiotensinconverting enzyme inhibitors cilazapril, quinapril and ramipril in pharmaceutical formulations, Il Farmaco ,2003,58:343
  • 2Cudina O, Jankovic I, Comor M, et al. Interaction of quinapril anion with cationic surfactant micelles of cetyltrimethylammonium bromide. J Colloid Inteface Sci,2006,301:692
  • 3Bonazzi D, Gotti R, Andrisano V, et al. Analysis of ACE inhibitors in pharmaceutical dosage forms by derivative UV spectroscopy and liquid chromatography (HPLC). J Pharm Biomed Anal, 1997,16:431
  • 4Hengy H, Most M. Determination of the new ace - inhibitor quinapril and its active metabolite quinaprilat in plasma and urine by high - performance liquid chromatography and pre - column labelling for fluorescent - detection. J Liquid Chromatogr, 1988,40:517
  • 5Goto N, Kamata T, Ikegami K. Trace analysis of quinapril and its active metabolite, quinaprilat, in human plasma and urine by gas chromatography - negative - ion chemical ionization mass spectrometry. J Chromatogr, 1992,578 (2) : 195
  • 6Ferry JJ, Horvath AM, Easton - Taylor M, et al. Determination of quinapril and its active metabolite in human plasma and urine by gas chromatography with electron - capture detection. J Chromatogr, 1987,421 ( 1 ) : 187
  • 7Abbara CH, Aymard G, Hinh S,et al. Simultaneous determination of quinapril and its active metabolite quinaprilat in human plasma using high - performance liquid chromatography with ultraviolet detection. J Chromatogr B,2002,766 : 199
  • 8Freed AL, Silbering SB, Kolodsick K J, et al. The development and stability assessment of extemporaneous pediatric formulations of Accupril, lnt J Pharm ,2005 ,304 : 135
  • 9侯旭彬,房玉兰,吴志军.高效液相色谱法测定盐酸喹那普利片含量[J].黑龙江医药,2001,14(5):345-346. 被引量：1
  • 10汪维鹏,丁黎.柱切换HPLC技术及其在体内药物分析中的应用[J].药学进展,2003,27(5):274-278. 被引量：5

引证文献1

二级引证文献3

中国处方药
2005年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部